Genomic Health

Genomic Health, Inc.

Company type	Public (until 2019)
Industry	Biotechnology
Founded	2000 (2000)
Founder	Randy Scott
Defunct	2019 (2019)
Fate	Acquired by Exact Sciences Corporation
Headquarters	Redwood City , United States
Area served	International (including Geneva and London offices)
Key people	Randy Scott (founder)
Products	Oncotype DX (genomic test for breast cancer recurrence)
Parent	Exact Sciences Corporation

Genomic Health, Inc. was a biotechnology firm focused on cancer diagnostics, with its main office located in Redwood City, California. In 2019, it became part of Exact Sciences Corporation through acquisition.

History

Established in 2000 by Randy Scott, who previously served as CEO of Incyte, Genomic Health was motivated by a personal connection to cancer and the promise of genome-driven therapies.

By 2003, the company introduced Oncotype DX, a genomic test designed to measure the likelihood of breast cancer recurrence. The development process spanned over three years and required an investment of $30 million, initially encountering doubts about the validity of genetic testing.

In July 2005, Genomic Health submitted paperwork for an initial public offering aiming to raise as much as $75 million, supported by investors such as Versant Ventures and Kleiner Perkins Caufield & Byers. The company began trading on the NASDAQ exchange under the ticker GHDX at a price of $12 per share.

In 2010, the company created a subsidiary called Invitae to unify various genetic tests; Invitae was later separated into an independent entity in 2012.

By 2011, Genomic Health had expanded internationally with offices established in Geneva and London.

Exact Sciences purchased Genomic Health in July 2019 for roughly $2.8 billion, aiming to enhance its range of medical diagnostic offerings.

See also

• Human genome
• Genetic testing